Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 27, 2026, 2:59 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 26 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Azelastine nasal spray Clear all
Completed Phase 3 Interventional Results available

Comparative Safety and Efficacy of Two Steroid Treatments in the Relief of the Symptoms of Seasonal Allergic Rhinitis

NCT02230696
View directory record Official record
Conditions
Seasonal Allergic Rhinitis
Interventions
Azelastine Hydrochloride/Fluticasone Propionate Nasal Spray, Placebo nasal spray
Drug
Lead sponsor
Padagis LLC
Industry
Eligibility
12 Years to 65 Years
Enrollment
951 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
30
States / cities
Stockbridge, Georgia • Louisville, Kentucky • Baltimore, Maryland + 21 more
Source: ClinicalTrials.gov public record
Updated Oct 21, 2021 · Synced Sep 27, 2026, 2:59 PM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Safety and Effectiveness of a Nasal Spray to Treat Perennial Allergies

NCT00712920
View directory record Official record
Conditions
Perennial Allergic Rhinitis
Interventions
0.15% azelastine hydrochloride, 0.1% azelastine hydrochloride, Placebo
Drug
Lead sponsor
Meda Pharmaceuticals
Industry
Eligibility
12 Years and older
Enrollment
581 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2007
U.S. locations
43
States / cities
Huntington Beach, California • Long Beach, California • Los Angeles, California + 35 more
Source: ClinicalTrials.gov public record
Updated Jun 7, 2011 · Synced Sep 27, 2026, 2:59 PM EDT
Completed Phase 4 Interventional

Investigation of the Efficacy and Safety of Concomitant Administration of Ciclesonide Nasal Spray and Azelastine Nasal Spray in Patients (18 Years or Older) With Perennial Allergic Rhinitis (PAR) Not Adequately Controlled on an Intranasal Corticosteroid or Antihistamine Monotherapy (BY9010/M1-490)

NCT00806754
View directory record Official record
Conditions
Rhinitis, Allergic, Perennial
Interventions
Ciclesonide nasal spray + placebo Azelastine, Ciclesonide nasal spray + Azelastine
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
340 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
35
States / cities
Encinitas, California • Los Angeles, California • Mission Viejo, California + 32 more
Source: ClinicalTrials.gov public record
Updated Nov 22, 2016 · Synced Sep 27, 2026, 2:59 PM EDT
Completed Phase 3 Interventional

A Study to Evaluate the Safety and Efficacy of a Nasal Spray to Treat Seasonal Allergies

NCT01368445
View directory record Official record
Conditions
Seasonal Allergic Rhinitis
Interventions
azelastine hydrochloride 0.15% Nasal Spray, azelastine hydrochloride 0.15% and Placebo, Azelastine 0.1%, Nasal Spray
Drug
Lead sponsor
Meda Pharmaceuticals
Industry
Eligibility
12 Years and older
Enrollment
617 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
30
States / cities
Fountain Valley, California • Long Beach, California • Los Angeles, California + 26 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2011 · Synced Sep 27, 2026, 2:59 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Evaluation of the Sensory Attributes of Olopatadine 0.6% and Azelastine 137mcg Nasal Sprays in Patients w/Allergic Rhinitis

NCT00772304
View directory record Official record
Conditions
Allergic Rhinitis
Interventions
Olopatadine 0.6% / Azelastine 137 mcg
Drug
Lead sponsor
Alcon Research
Industry
Eligibility
18 Years and older
Enrollment
102 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2008
U.S. locations
1
States / cities
Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Mar 1, 2010 · Synced Sep 27, 2026, 2:59 PM EDT
Completed Phase 4 Interventional Results available

Safety of Astepro 0.15% Nasal Spray and Astepro 0.1% Nasal Spray in Children Ages >6 Months to <6 Years With AR

NCT01880840
View directory record Official record
Conditions
Allergic Rhinitis
Interventions
205.5 mcg of azelastine hydrochloride, 137 mcg of azelastine hydrochloride
Drug
Lead sponsor
Meda Pharmaceuticals
Industry
Eligibility
6 Months to 5 Years
Enrollment
191 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
14
States / cities
Birmingham, Alabama • Little Rock, Alaska • Costa Mesa, California + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2015 · Synced Sep 27, 2026, 2:59 PM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Safety and Effectiveness of a Nasal Spray to Treat Seasonal Allergies

NCT00651118
View directory record Official record
Conditions
Seasonal Allergic Rhinitis
Interventions
Placebo, azelastine Hcl, azelastineHcl / fluticasone propionate, fluticasone propionate
Drug
Lead sponsor
Meda Pharmaceuticals
Industry
Eligibility
12 Years and older
Enrollment
832 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
43
States / cities
Scottsdale, Arizona • Encinitas, California • Los Angeles, California + 38 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2012 · Synced Sep 27, 2026, 2:59 PM EDT
Completed Phase 3 Interventional Results available

A Study Evaluating the Safety and Effectiveness of a Nasal Spray to Treat Seasonal Allergies

NCT00740792
View directory record Official record
Conditions
Seasonal Allergic Rhinitis
Interventions
azelastine HCl/fluticasone propionate, azelastine Hcl, fluticasone propionate, placebo
Drug
Lead sponsor
Meda Pharmaceuticals
Industry
Eligibility
12 Years and older
Enrollment
776 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
39
States / cities
Scottsdale, Arizona • Encinitas, California • Fountain Valley, California + 32 more
Source: ClinicalTrials.gov public record
Updated Sep 6, 2012 · Synced Sep 27, 2026, 2:59 PM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Safety and Efficacy of Two Nasal Sprays to Treat Seasonal Allergies

NCT00720278
View directory record Official record
Conditions
Seasonal Allergic Rhinitis
Interventions
0.15% azelastine hydrochloride 1644 mcg daily, 0.1% azelastine hydrochloride 1096 mcg daily, Placebo
Drug
Lead sponsor
Meda Pharmaceuticals
Industry
Eligibility
12 Years and older
Enrollment
526 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
29
States / cities
Oxford, Alabama • Encinitas, California • Los Angeles, California + 25 more
Source: ClinicalTrials.gov public record
Updated Mar 1, 2010 · Synced Sep 27, 2026, 2:59 PM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

A Pilot Clinical Evaluation of Astepro® Nasal Spray for Management of Early SARS-CoV-2 Infection

NCT06008860
View directory record Official record
Conditions
COVID-19
Interventions
Experimental: Primary Cohort, Placebo Comparator: Primary Cohort - Placebo
Drug · Other
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
280 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 9, 2025 · Synced Sep 27, 2026, 2:59 PM EDT
Completed Phase 4 Interventional Results available

Safety and Efficacy of Olopatadine 0.6% and Azelastine 137 Mcg in Vasomotor Rhinitis

NCT00979615
View directory record Official record
Conditions
Vasomotor Rhinitis
Interventions
Olopatadine HCL (Patanase) Nasal Spray, 0.6%, Azelastine HCl (Astelin) Nasal Spray, 137 mcg
Drug
Lead sponsor
Alcon Research
Industry
Eligibility
12 Years and older
Enrollment
129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2009
U.S. locations
1
States / cities
Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated May 9, 2011 · Synced Sep 27, 2026, 2:59 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

3 Month Safety Study of Dymista Nasal Spray and Fluticasone Propionate in Children 4-11 Years of Age With Allergic Rhinitis

NCT01794741
View directory record Official record
Conditions
Allergic Rhinitis
Interventions
Dymista Nasal Spray, Fluticasone propionate nasal spray
Drug
Lead sponsor
Meda Pharmaceuticals
Industry
Eligibility
4 Years to 11 Years
Enrollment
405 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2013
U.S. locations
41
States / cities
Birmingham, Alabama • Little Rock, Alaska • Costa Mesa, California + 34 more
Source: ClinicalTrials.gov public record
Updated Mar 30, 2015 · Synced Sep 27, 2026, 2:59 PM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Safety and Effectiveness of a Nasal Spray to Treat Seasonal Allergies

NCT00660517
View directory record Official record
Conditions
Seasonal Allergic Rhinitis
Interventions
MP29-02, azelastine Hcl, fluticasone propionate, placebo
Drug
Lead sponsor
Meda Pharmaceuticals
Industry
Eligibility
12 Years and older
Enrollment
607 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
7
States / cities
Austin, Texas • New Braunfels, Texas • San Antonio, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 26, 2012 · Synced Sep 27, 2026, 2:59 PM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Safety and Efficacy of a Nasal Spray to Treat Children With Perennial Allergic Rhinitis

NCT01018862
View directory record Official record
Conditions
Perennial Allergic Rhinitis
Interventions
Azelastine hydrochloride nasal spray 0.15%, Azelastine hydrochloride nasal spray 0.10%, Placebo
Drug
Lead sponsor
Meda Pharmaceuticals
Industry
Eligibility
6 Years to 12 Years
Enrollment
489 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
39
States / cities
Costa Mesa, California • Long Beach, California • Mission Viejo, California + 34 more
Source: ClinicalTrials.gov public record
Updated Jun 10, 2012 · Synced Sep 27, 2026, 2:59 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy Trial of Dymista Nasal Spray in Children Ages 4 to 11 With Seasonal Allergic Rhinitis (SAR)

NCT01915823
View directory record Official record
Conditions
Seasonal Allergic Rhinitis
Interventions
azelastine hydrochloride and fluticasone propionate, Dymista vehicle
Drug
Lead sponsor
Meda Pharmaceuticals
Industry
Eligibility
4 Years to 11 Years
Enrollment
348 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2013
U.S. locations
31
States / cities
Birmingham, Alabama • Little Rock, Alaska • Atlanta, Georgia + 24 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2015 · Synced Sep 27, 2026, 2:59 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Nasal Ocular Reflexes Contribute to Eye Symptoms

NCT00117832
View directory record Official record
Conditions
Rhinitis, Allergic, Seasonal
Interventions
Azelastine nasal spray
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 45 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2006
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 4, 2013 · Synced Sep 27, 2026, 2:59 PM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Safety and Effectiveness of a Nasal Spray to Treat Seasonal Allergies

NCT00883168
View directory record Official record
Conditions
Seasonal Allergic Rhinitis
Interventions
Placebo, azelastineHcl, fluticasone propionate, azelastine Hcl/fluticasone propionate
Drug
Lead sponsor
Meda Pharmaceuticals
Industry
Eligibility
12 Years and older
Enrollment
1,791 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
45
States / cities
Scottsdale, Arizona • Encinitas, California • Fountain Valley, California + 35 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2013 · Synced Sep 27, 2026, 2:59 PM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Safety & Effectiveness of a Nasal Spray to Treat Seasonal Allergies

NCT00719862
View directory record Official record
Conditions
Seasonal Allergic Rhinitis
Interventions
Placebo nasal spray, 0.15% azelastine hydrochloride Nasal Spray
Drug
Lead sponsor
Meda Pharmaceuticals
Industry
Eligibility
12 Years and older · Female only
Enrollment
481 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
34
States / cities
Huntington Beach, California • Long Beach, California • San Diego, California + 30 more
Source: ClinicalTrials.gov public record
Updated Feb 1, 2010 · Synced Sep 27, 2026, 2:59 PM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Safety and Effectiveness of a Nasal Spray to Treat Seasonal Allergies

NCT00824473
View directory record Official record
Conditions
Seasonal Allergic Rhinitis
Interventions
Placebo, 0.15% azelastine hydrochloride
Drug
Lead sponsor
Meda Pharmaceuticals
Industry
Eligibility
12 Years and older
Enrollment
506 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
7
States / cities
Austin, Texas • New Braunfels, Texas • San Antonio, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 22, 2010 · Synced Sep 27, 2026, 2:59 PM EDT
Not listed Phase 3 Interventional

Clinical Equivalence of Azelastine Hydrochloride and Fluticasone Propionate, 137/50 mcg Nasal Spray to Dymista™

NCT02249663
View directory record Official record
Conditions
Seasonal Allergic Rhinitis
Interventions
Azelastine hydrochloride and Fluticasone propionate, Dymista™, Placebo
Drug · Other
Lead sponsor
Teva Pharmaceuticals USA
Industry
Eligibility
12 Years and older
Enrollment
1,535 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2014
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 24, 2014 · Synced Sep 27, 2026, 2:59 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Factors Involved in Dymista's Superior Clinical Efficacy in the Treatment of Seasonal Allergic Rhinitis

NCT02402465
View directory record Official record
Conditions
Allergic Rhinitis
Interventions
Placebo, Fluticasone propionate, Fluticasone/Azelastine nasal spray, Nasal Allergen Challenge
Drug · Procedure
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 55 Years
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2020
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 16, 2024 · Synced Sep 27, 2026, 2:59 PM EDT
Not listed Phase 4 Interventional Accepts healthy volunteers

Efficacy of Azelastine and Mometasone Irrigation in Comparison to Nasal Sprays in Patients With Chronic Rhinitis

NCT05626621
View directory record Official record
Conditions
Chronic Rhinitis
Interventions
Azelastine (137 mcg/spray) Nasal Spray and Mometasone (50 mcg/spray) Nasal Spray, Mometasone Nasal Irrigation (1 mg capsule), Mometasone (1 mg) and Azelastine (1 mg) Nasal Irrigation
Drug
Lead sponsor
Endeavor Health
Other
Eligibility
18 Years and older
Enrollment
81 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
1
States / cities
Evanston, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 27, 2023 · Synced Sep 27, 2026, 2:59 PM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate the Safety and Tolerability of a Nasal Spray in Patients With Chronic Allergic or Nonallergic Rhinitis

NCT00783432
View directory record Official record
Conditions
Chronic Allergic Rhinitis, Nonallergic Rhinitis
Interventions
Astepro Nasal Spray (0.1% azelastine hydrochloride), Astelin Nasal Spray (0.1% azelastine hydrochloride)
Drug
Lead sponsor
Meda Pharmaceuticals
Industry
Eligibility
12 Years and older
Enrollment
862 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Somerset, New Jersey
Source: ClinicalTrials.gov public record
Updated Oct 5, 2009 · Synced Sep 27, 2026, 2:59 PM EDT
Completed Phase 4 Interventional Results available

Comparison of Seasonal Allergic Rhinitis Treatment With 2 Antihistamines Used in Combination With Intranasal Corticosteroid

NCT00845195
View directory record Official record
Conditions
Seasonal Allergic Rhinitis
Interventions
Olopatadine HCl Nasal Spray, 0.6%, Azelastine HCl Nasal Spray, 0.1%
Drug
Lead sponsor
Alcon Research
Industry
Eligibility
12 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2009
U.S. locations
1
States / cities
Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Apr 26, 2010 · Synced Sep 27, 2026, 2:59 PM EDT